# The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/the-ohio-state-university-comprehensive-cancer-center-arthur-g-james-cancer/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 68.3 |
| Citations | 932,426 |
| City | Columbus |
| Country | US |
| Description | The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute is a research organisation in Columbus, US. OpenAlex records 8,214 works and 932,426 citations for it. 1,929 researchers list it as their most recent affiliation. |
| Homepage | https://cancer.osu.edu/ |
| OpenAlex ID | https://openalex.org/I2799885155 |
| Researchers | 1,929 |
| ROR ID | https://ror.org/028t46f04 |
| Type | healthcare |
| Wikidata ID | https://www.wikidata.org/wiki/Q14716521 |
| Works | 8,214 |

## University papers

Showing 12 of 138.

- [Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial](https://scholariq.org/papers/erlotinib-versus-standard-chemotherapy-as-first-line-treatment-for-european/)
- [The 2011 Report on Dietary Reference Intakes for Calcium and Vitamin D from the Institute of Medicine: What Clinicians Need to Know](https://scholariq.org/papers/the-2011-report-on-dietary-reference-intakes-for-calcium-and-vitamin-d-from-the/)
- [Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden](https://scholariq.org/papers/nivolumab-plus-ipilimumab-in-lung-cancer-with-a-high-tumor-mutational-burden/)
- [First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer](https://scholariq.org/papers/first-line-nivolumab-in-stage-iv-or-recurrent-non-small-cell-lung-cancer/)
- [Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial](https://scholariq.org/papers/olaparib-tablets-as-maintenance-therapy-in-patients-with-platinum-sensitive/)
- [Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/rucaparib-maintenance-treatment-for-recurrent-ovarian-carcinoma-after-response/)
- [Absence of Monocyte Chemoattractant Protein-1 Reduces Atherosclerosis in Low Density Lipoprotein Receptor–Deficient Mice](https://scholariq.org/papers/absence-of-monocyte-chemoattractant-protein-1-reduces-atherosclerosis-in-low/)
- [<i>ROS1</i> Rearrangements Define a Unique Molecular Class of Lung Cancers](https://scholariq.org/papers/i-ros1-i-rearrangements-define-a-unique-molecular-class-of-lung-cancers/)
- [Mitochondrial Dynamics Controls T Cell Fate through Metabolic Programming](https://scholariq.org/papers/mitochondrial-dynamics-controls-t-cell-fate-through-metabolic-programming/)
- [Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology](https://scholariq.org/papers/non-small-cell-lung-cancer-version-3-2022-nccn-clinical-practice-guidelines-in/)
- [Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial](https://scholariq.org/papers/activity-and-safety-of-nivolumab-an-anti-pd-1-immune-checkpoint-inhibitor-for/)
- [Caspase-1-induced pyroptosis is an innate immune effector mechanism against intracellular bacteria](https://scholariq.org/papers/caspase-1-induced-pyroptosis-is-an-innate-immune-effector-mechanism-against/)

## University researchers

- [David M. O’Malley](https://scholariq.org/researchers/david-m-o-malley/)
- [Steven K. Clinton](https://scholariq.org/researchers/steven-k-clinton/)
- [Mark D. Wewers](https://scholariq.org/researchers/mark-d-wewers/)
- [Arnab Chakravarti](https://scholariq.org/researchers/arnab-chakravarti/)
- [Alexa Meara](https://scholariq.org/researchers/alexa-meara/)
- [Jeffery Chakedis](https://scholariq.org/researchers/jeffery-chakedis/)

## University top topics

Showing 8 of 25.

- [Lymphoma Diagnosis and Treatment](https://scholariq.org/topics/lymphoma-diagnosis-and-treatment/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Ovarian cancer diagnosis and treatment](https://scholariq.org/topics/ovarian-cancer-diagnosis-and-treatment/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Glioma Diagnosis and Treatment](https://scholariq.org/topics/glioma-diagnosis-and-treatment/)
- [Head and Neck Cancer Studies](https://scholariq.org/topics/head-and-neck-cancer-studies/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.